CINGW
Price:
$0.0413
Market Cap:
$15.16M
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.[Read more]
Industry
Biotechnology
IPO Date
Stock Exchange
NASDAQ
Ticker
CINGW
According to Cingulate Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.35. This represents a change of 200.01% compared to the average of 2.45 of the last 4 quarters.
The mean historical Current Ratio of Cingulate Inc. over the last ten years is 3.62. The current 7.35 Current Ratio has changed 20.23% with respect to the historical average. Over the past ten years (40 quarters), CINGW's Current Ratio was at its highest in in the December 2021 quarter at 16.05. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
3.62
Median
0.53
Minimum
0.06
Maximum
16.05
Discovering the peaks and valleys of Cingulate Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 2.91%
Maximum Annual Current Ratio = 16.05
Minimum Annual Increase = -94.96%
Minimum Annual Current Ratio = 0.06
Year | Current Ratio | Change |
---|---|---|
2023 | 0.06 | -94.96% |
2022 | 1.12 | -93.01% |
2021 | 16.05 | 2.91% |
2020 | 0.53 | 60.63% |
The current Current Ratio of Cingulate Inc. (CINGW) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
5.74
5-year avg
3.62
10-year avg
3.62
Cingulate Inc.’s Current Ratio is less than Cingulate Inc. (7.35), greater than Celularity Inc. (0.26), greater than NeuroSense Therapeutics Ltd. (0.46), less than EQRx, Inc. (18.78), greater than Dermata Therapeutics, Inc. (7.11),
Company | Current Ratio | Market cap |
---|---|---|
7.35 | $15.16M | |
0.26 | $93.64M | |
0.46 | $10.92M | |
18.78 | $1.14B | |
7.11 | $2.96M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cingulate Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Cingulate Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Cingulate Inc.'s Current Ratio?
How is the Current Ratio calculated for Cingulate Inc. (CINGW)?
What is the highest Current Ratio for Cingulate Inc. (CINGW)?
What is the 3-year average Current Ratio for Cingulate Inc. (CINGW)?
What is the 5-year average Current Ratio for Cingulate Inc. (CINGW)?
How does the current Current Ratio for Cingulate Inc. (CINGW) compare to its historical average?